true
Icon to close the modal
Support
West Africa
Phone Icon
+233 302 769 692
West Africa Secant Tower West Wings, 4th Floor, Secant Tower, Plot #398, Papa Monrovia Street, 7th Lane Osu Kuku Hills, Accra Ghana
Modal Close Icon
Icon to close thank you modal
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
East Africa
Phone Icon
+254 20 2738339/40
Africa Re Center, 2nd FL, Hospital Rd, Upper Hill, P.O. Box 76613 – 00508, Nairobi, Kenya
Fax Icon
+254 758 726613
East & West Africa
Location Icon
ODE.africa@bd.com
serviceclaims.africa@bd.com
South Africa
Phone Icon
+27 10 201 7400
20 Woodlands Drive, The Woodllands Office Park Build 6 (G), Woodmead, Johannesburg, Gauteng, 2191
orderssa@bd.com

BD PhaSeal™ Optima system

The next-generation Closed-System Drug-Transfer Device (CSTD) from BD that advances hazardous drug protection

Contact Us
phaseal-optima_1R_171005_Group_PHarma_1_185_Retouched_Original_cropped
phaseal-optima_3_Clean_Rm_0278
phaseal-optima_4_171005_InUse_Prep_1a_024_Retouched_Original
phaseal-optima_5_171005_InUse_Prep_1b_046_Retouched_Original
phaseal-optima_6_171005_InUse_Prep_2b_069_Retouched_Original
phaseal-optima_7_171005_InUse_admin_2a_095_Retouched_Original
BD PhaSeal™ Optima system

Ready to learn more? Let’s have a conversation.

Loading

Overview

Safety. Performance. Ergonomics. Ease of use. We've optimized every component, and the result is a CSTD with design innovations that advance hazardous drug safety. The BD PhaSeal™ Optima system meets the requirements of the NIOSH IPA draft CSTD-test protocol‡, a robust test protocol applicable to barrier-type closed system drug transfer devices.1,2

true
Features and Benefits

Airtight

Every component is designed with no inlets or air exchange for completely airtight hazardous drug transfers.

Demonstrated

The BD PhaSeal™ Optima system prevents microbial ingress for up to 168 hours and 10 penetrations*†

Efficient

The BD PhaSeal™ Optima system minimizes residual drug loss in vials compared to other similar system.

User-validated

Feedback from longstanding CSTD users and traditional technique users guided us to optimize and innovate the design.

Design innovations

Safety

  • Injector designed to prevent accidental needlesticks
  • Self-sealing membranes for leakproof connections

Performance

  • Proprietary Protector design to maximize drug extraction
  • Compatible with ISO-compliant Luer lock syringes and IV sets

Ergonomics

  • Power grip and straight motion to connect and disconnect, aligned with NIOSH recommendations to avoid pinch grip3
  • Optimized design for clinician comfort

Ease of use

  • Intuitive one-step straight-push connection to aid workflow
  • Can connect without alignment to help minimize learning curve

Related Videos

BD PhaSeal™ Optima Video for Pharmacy

BD PhaSeal™ Optima for Nursing

EIFUs
Resources

References

Please note, not all products, services or features of products and services may be available in your local area. Please check with your local BD representative.

Notes

‡2015
*Within an ISO Class V environment following aseptic technique.
†The ability to prevent microbial ingress for up to 168 hours should not be interpreted as modifying, extending or superseding a manufacturer's labeling recommendations for the storage and expiration dating of the drug vial. Refer to drug manufacturer’s recommendations and USP compounding guidelines for shelf life and sterility information.

 

References

  1. National Institute for Occupational Safety and Health (NIOSH). A vapor containment performance protocol for closed system transfer devices used during pharmacy compounding and administration of hazardous drugs. https://www.cdc.gov/niosh/docket/review/docket288/pdfs/a-vapor-containment-performance-protocol-for-closed-system-transfer-devices.pdf. Accessed May 26, 2020.
  2. BD-8440 BD PhaSeal Optima Vapor Containment White Paper.
  3. Easy Ergonomics: A Guide to Selecting Non-Powered Hand Tools. Centers for Disease Control and Prevention website. https://www.cdc.gov/niosh/docs/2004-164/pdfs/2004-164.pdf. Published August 18, 2004. Accessed April 22, 2020.

BD-20816

true